Abaloparatide TFA
Based on 3 publication(s) in Google Scholar
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.80%
- 화학식: C176H301N56F3O51
- 분자량:4074.61
-
보관:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Abaloparatide TFA
MoreAll Arrestin Isoforms
More
Biological Activity
Parathyroid hormone receptor 1 (PTHR1)[1]
Abaloparatide TFA (0-100 nM; 40 min) enhances Gs/cAMP signaling and β-arrestin recruitment in MC3T3-E1 cells[1].
Abaloparatide TFA (0-100 nM) efficiently induces PTHR1 internalization in a dose-dependen manner with an EC50 value of 0.8 nM in U2OS Cell[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Sprague-Dawley rats (age 22 weeks)[2]
-
Dosage:1 µg/kg, 5 µg/kg, 25 µg/kg
-
Administration:Subcutaneous injection; daily; for 12 months
-
Result:Increased biochemical bone formation markers, histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces. Induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) was increasing 25%.
-
Animal Model:16-week-old wild-type (WT) female C57BL/6J mice[1]
-
Dosage:20-80 µg/kg
-
Administration:S.c.; daily for 30 days
-
Result:Efficiently expanded cortical thickness (Ct. Th) at both doses of 20 and 80 µg/kg/day by 17% and 18%, respectively, increased P1NP levels to 227% and 407% at 20 and 80 µg/kg/day, respectively.
Chemical Information
-
Appearance Solid
-
분자량 4074.61
-
화학식 C176H301N56F3O51
-
Color White to off-white
-
Synonyms
BA 058 TFA; BIM 44058 TFA
-
Sequence
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-{Aib}-Lys-Leu-His-Thr-Ala-NH2
-
Sequence Shortening
AVSEHQLLHDKGKSIQDLRRRELLEKLL-{Aib}-KLHTA-NH2
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
Activation of PTH1R alleviates epididymitis and orchitis through Gq and β-arrestin-1 pathways. [Abstract]2021 Nov 9;118(45):e2107363118. PMID: 34740971 -
Biomater Adv
A dual-active biological scaffold with in situ loaded Abaloparatide and bone marrow-derived mesenchymal stem cells synergistically regulatory T cell to promote bone regeneration. [Abstract]2026 May:182:214700. PMID: 41506099 -
BMC Oral Health
The effects of abaloparatide on alveolar bone loss in postmenopausal osteoporotic rats with periodontitis. [Abstract]2025 Sep 29;25(1):1492. PMID: 41023931
용액&용해도
H2O : 100 mg/mL (24.54 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 20 mg/mL (4.91 mM); Clear solution; Need ultrasonic and warming
순도&문서
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sahbani K, et al. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep. 2019 Oct;7(19):e14225. [Content Brief]
[2]. Varela A, et al. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. J Bone Miner Res. 2017 Jan;32(1):24-33. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.2454 mL | 1.2271 mL | 2.4542 mL | 6.1356 mL |
| 5 mM | 0.0491 mL | 0.2454 mL | 0.4908 mL | 1.2271 mL | |
| 10 mM | 0.0245 mL | 0.1227 mL | 0.2454 mL | 0.6136 mL | |
| 15 mM | 0.0164 mL | 0.0818 mL | 0.1636 mL | 0.4090 mL | |
| 20 mM | 0.0123 mL | 0.0614 mL | 0.1227 mL | 0.3068 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Abaloparatide TFA Related Classifications
HY-108742A Related Classifications
Powered by Bioz